234 related articles for article (PubMed ID: 10571597)
21. Review article: clinical pharmacology of alosetron.
Gunput MD
Aliment Pharmacol Ther; 1999 May; 13 Suppl 2():70-6. PubMed ID: 10429744
[TBL] [Abstract][Full Text] [Related]
22. The effect of the 5-HT3 receptor antagonist, alosetron, on brain responses to visceral stimulation in irritable bowel syndrome patients.
Mayer EA; Berman S; Derbyshire SW; Suyenobu B; Chang L; Fitzgerald L; Mandelkern M; Hamm L; Vogt B; Naliboff BD
Aliment Pharmacol Ther; 2002 Jul; 16(7):1357-66. PubMed ID: 12144587
[TBL] [Abstract][Full Text] [Related]
23. Effect of alosetron on bowel urgency and global symptoms in women with severe, diarrhea-predominant irritable bowel syndrome: analysis of two controlled trials.
Lembo AJ; Olden KW; Ameen VZ; Gordon SL; Heath AT; Carter EG
Clin Gastroenterol Hepatol; 2004 Aug; 2(8):675-82. PubMed ID: 15290660
[TBL] [Abstract][Full Text] [Related]
24. Pharmacology and clinical experience with alosetron.
Camilleri M
Expert Opin Investig Drugs; 2000 Jan; 9(1):147-59. PubMed ID: 11060667
[TBL] [Abstract][Full Text] [Related]
25. Drug therapy options for patients with irritable bowel syndrome.
Talley NJ
Am J Manag Care; 2001 Jul; 7(8 Suppl):S261-7. PubMed ID: 11474911
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials.
Cremonini F; Delgado-Aros S; Camilleri M
Neurogastroenterol Motil; 2003 Feb; 15(1):79-86. PubMed ID: 12588472
[TBL] [Abstract][Full Text] [Related]
27. Patient satisfaction with alosetron for the treatment of women with diarrhea-predominant irritable bowel syndrome.
Olden K; DeGarmo RG; Jhingran P; Bagby B; Decker C; Markowitz M; Carter E; Bobbitt W; Dahdul A; DeCastro E; Gringeri L; Johanson J; Levinson L; Mula G; Poleynard G; Stoltz RR; Truesdale R; Young D;
Am J Gastroenterol; 2002 Dec; 97(12):3139-46. PubMed ID: 12492201
[TBL] [Abstract][Full Text] [Related]
28. Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials.
Andresen V; Montori VM; Keller J; West CP; Layer P; Camilleri M
Clin Gastroenterol Hepatol; 2008 May; 6(5):545-55. PubMed ID: 18242143
[TBL] [Abstract][Full Text] [Related]
29. Alosetron improves quality of life in women with diarrhea-predominant irritable bowel syndrome.
Watson ME; Lacey L; Kong S; Northcutt AR; McSorley D; Hahn B; Mangel AW
Am J Gastroenterol; 2001 Feb; 96(2):455-9. PubMed ID: 11232690
[TBL] [Abstract][Full Text] [Related]
30. Mebeverine alters small bowel motility in irritable bowel syndrome.
Evans PR; Bak YT; Kellow JE
Aliment Pharmacol Ther; 1996 Oct; 10(5):787-93. PubMed ID: 8899088
[TBL] [Abstract][Full Text] [Related]
31. Alosetron and irritable bowel syndrome.
Mayer EA; Bradesi S
Expert Opin Pharmacother; 2003 Nov; 4(11):2089-98. PubMed ID: 14596662
[TBL] [Abstract][Full Text] [Related]
32. Adequate relief as an endpoint in clinical trials in irritable bowel syndrome.
Mangel AW; Hahn BA; Heath AT; Northcutt AR; Kong S; Dukes GE; McSorley D
J Int Med Res; 1998; 26(2):76-81. PubMed ID: 9602985
[TBL] [Abstract][Full Text] [Related]
33. Comparative efficacy and safety of trimebutine versus mebeverine in the treatment of irritable bowel syndrome.
Rahman MZ; Ahmed DS; Mahmuduzzaman M; Rahman MA; Chowdhury MS; Barua R; Ishaque SM
Mymensingh Med J; 2014 Jan; 23(1):105-13. PubMed ID: 24584382
[TBL] [Abstract][Full Text] [Related]
34. Alosetron (Lotronex) for treatment of irritable bowel syndrome.
Med Lett Drugs Ther; 2000 Jun; 42(1081):53-4. PubMed ID: 10872030
[No Abstract] [Full Text] [Related]
35. Alosetron.
Balfour JA; Goa KL; Perry CM
Drugs; 2000 Mar; 59(3):511-8; discussion 519-20. PubMed ID: 10776833
[TBL] [Abstract][Full Text] [Related]
36. Effect of a calcium channel blocker and antispasmodic in diarrhoea-predominant irritable bowel syndrome.
Lu CL; Chen CY; Chang FY; Chang SS; Kang LJ; Lu RH; Lee SD
J Gastroenterol Hepatol; 2000 Aug; 15(8):925-30. PubMed ID: 11022835
[TBL] [Abstract][Full Text] [Related]
37. Comparison of two different formulations of mebeverine hydrochloride in irritable bowel syndrome.
Gilbody JS; Fletcher CP; Hughes IW; Kidman SP
Int J Clin Pract; 2000 Sep; 54(7):461-4. PubMed ID: 11070572
[TBL] [Abstract][Full Text] [Related]
38. A systematic review of efficacy and tolerability of mebeverine in irritable bowel syndrome.
Darvish-Damavandi M; Nikfar S; Abdollahi M
World J Gastroenterol; 2010 Feb; 16(5):547-53. PubMed ID: 20128021
[TBL] [Abstract][Full Text] [Related]
39. Cognitive behaviour therapy in addition to antispasmodic treatment for irritable bowel syndrome in primary care: randomised controlled trial.
Kennedy T; Jones R; Darnley S; Seed P; Wessely S; Chalder T
BMJ; 2005 Aug; 331(7514):435. PubMed ID: 16093252
[TBL] [Abstract][Full Text] [Related]
40. [The irritable colon syndrome. New therapeutic possibilities in the treatment of a frequent syndrome].
Eisenburg J; Kruis W; Schüssler P; Weinzierl M
Fortschr Med; 1978 Nov; 96(41):2064-70. PubMed ID: 700592
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
